Nanobesity
The Nanobesity product is a disruptive nanomolecule for nasal administration, targeting hypothalamic areas to regulate appetite, food intake, and insulin resistance. These protein-based nanomolecules, optimized for size, zeta potential, mucoadhesion, and biocompatibility, reach brain cells via intranasal delivery, overcoming current nanomedicine limitations. This cost-effective, scalable technology provides a homogeneous formulation with superior biocompatibility compared to existing brain delivery platforms. It will be the first brain-targeted nanomedicine to address obesity and diabetes, avoiding the off-target effects, toxicity, and inefficiencies of current treatments.